Development of a New Isoxsuprine Hydrochloride-Based Hydroxylated Compound with Potent Antioxidant and Anti-Inflammatory Activities

Chien-Yu Wu, Hsiou‐Yu Ding, Tzi‐Yuan Wang, Chunwei Liu, Jiumn‐Yih Wu, Te‐Sheng ChangJournal of Microbiology and Biotechnology 2024 · DOI

Abstract

The scientific community actively pursues novel compounds with biological activities. In this context, our study utilized the predicted data mining approach (PDMA), which can efficiently screen out biotransformable precursor candidates to produce new bioactive compounds. The PDMA was applied to Bacillus megaterium tyrosinase (BmTYR) to form new bioactive hydroxyl compounds from isoxsuprine hydrochloride (isoxsuprine). The results show that isoxsuprine could be biotransformed by BmTYR to form a new compound, 3''-hydroxyisoxsuprine. 3''-Hydroxyisoxsuprine exhibited 40-fold and 10-fold higher potent antioxidant and anti-inflammation activities than the precursor, isoxsuprine. The 3''-hydroxyisoxsuprine effectively mitigates the hyperimmune response in RAW 264.7 macrophages by inhibiting the upregulation of pro-inflammatory cytokine (IL-1β and IL-6) and inflammatory enzyme COX-2 gene expression triggered by LPS stimulation. This study illustrates that PDMA is an effective strategy for screening known natural and chemical compounds and for generating new bioactive compounds through biotransformation. Our newly produced compound has potential future applications in pharmacology and biotechnology.

Introduction

The pharmaceutical industry faces a dual challenge: the high cost and environmental impact of traditional chemical synthesis, and the "needle in a haystack" difficulty of discovering new bioactive compounds. While biotransformation—using enzymes to modify molecules—offers a greener, more precise alternative, finding the right combination of enzyme and precursor often relies on slow, expensive trial-and-error.

Researchers successfully "upgraded" the common vasodilator drug isoxsuprine into a novel bioactive compound using a targeted enzymatic approach. By employing a predictive data mining strategy and bacterial tyrosinase, they created a hydroxylated derivative that is significantly more potent as an antioxidant and more effective at reducing inflammation than its parent molecule. This paper validates a Predicted Data Mining Approach (PDMA) to move away from random screening toward a systematic method for identifying existing chemicals that can be transformed into high-value therapeutics.

Methods

The researchers combined computational screening with "wet lab" biocatalysis:

  1. PDMA Screening: Candidates were selected based on three criteria: structural mimicry of tyrosine (the natural substrate for the chosen enzyme), availability at a gram-scale for industrial feasibility, and novelty of the resulting product.
  2. Biotransformation: Tyrosinase from Bacillus megaterium (BmTYR) was used as the biocatalyst. This enzyme performs "ortho-hydroxylation," adding a hydroxyl (-OH) group next to an existing one on a phenol ring to create a catechol structure, a motif often associated with high bioactivity.
Chemical structure of isoxsuprine (A) and the general biotransformation scheme for producing catecholic intermediates (B).
  1. Structural Characterization: The new compound was purified via HPLC and its structure was mapped using High-Resolution Mass Spectrometry (HRMS) and multi-dimensional NMR (COSY, HSQC, and HMBC).
  2. Biological Assays: Antioxidant capacity was evaluated via DPPH assays. Anti-inflammatory effects were measured by nitric oxide (NO) production and gene expression (via Real-time PCR) in RAW 264.7 macrophage cells stimulated with LPS.

Key Results

The study successfully synthesized 3''-hydroxyisoxsuprine, a previously undocumented derivative. HPLC analysis confirmed the successful biotransformation of the precursor into the novel compound.

HPLC chromatograms showing the conversion of isoxsuprine (A) to the novel compound 3''-hydroxyisoxsuprine (B).
  • Antioxidant Potency: The new compound showed an IC50 of 39.7 μM in the DPPH assay, representing a 40-fold improvement over the parent isoxsuprine (IC50 > 4 mM).
  • Anti-Inflammatory Activity: In macrophage cells, the derivative inhibited nitric oxide production with an IC50 of 39.9 μM, making it 7 to 10 times more potent than isoxsuprine.
  • Gene Regulation: Real-time PCR confirmed that the compound significantly downregulated the expression of pro-inflammatory cytokines IL-1β and IL-6, as well as the inflammatory enzyme COX-2.

Discussion and Insights

  • The Power of the Catechol Group: The study reinforces a key principle in medicinal chemistry: adding a second hydroxyl group to a phenolic ring (forming a catechol) can exponentially increase a molecule's ability to scavenge free radicals and inhibit inflammatory pathways.
  • Precision Repurposing: Isoxsuprine is a well-known vasodilator. This research shows that "old" drugs can serve as excellent scaffolds for "new" bioactives with entirely different primary therapeutic targets.
  • Efficiency of PDMA: By using structural mimicry as a guide, the researchers bypassed the need to screen thousands of random molecules, demonstrating that targeted biotransformation is a viable shortcut in drug development.

Conclusion and Future Work

While the bioactivity of 3''-hydroxyisoxsuprine is clear, the exact molecular mechanisms—how specifically the compound interacts with cellular signaling pathways—require further investigation.

Future work will focus on integrating software-assisted molecular docking simulations into the PDMA workflow. This would allow researchers to predict not just if a compound can be transformed, but how efficiently the enzyme will process it and how strongly the resulting product will bind to human therapeutic targets. Additionally, assessing the feasibility of large-scale commercial production remains a necessary next step.

Summary updated

Abstract

The scientific community actively pursuits novel compounds with biological activities. In this context, our study utilized the predicted data mining approach (PDMA), which can efficiently screen out biotransformable precursor candidates to produce new bioactive compounds. The PDMA was applied to <i>Bacillus megaterium</i> tyrosinase (<i>Bm</i>TYR) to form new bioactive hydroxyl compounds from isoxsuprine hydrochloride (isoxsuprine). The results show that isoxsuprine could be biotransformed by <i>Bm</i>TYR to form a new compound, 3''-hydroxyisoxsuprine. 3''-Hydroxyisoxsuprine exhibited 40-fold and 10-fold higher potent antioxidant and anti-inflammation activities than the precursor, isoxsuprine. The 3''-hydroxyisoxsuprine effectively mitigates the hyperimmune response in RAW 264.7 macrophages by inhibiting the upregulation of pro-inflammatory cytokine (IL-1β and IL-6) and inflammatory enzyme COX-2 gene expression triggered by LPS stimulation. This study illustrates that PDMA is an effective strategy for screening known natural and chemical compounds and for generating new bioactive compounds through biotransformation. Our newly produced compound has potential future applications in pharmacology and biotechnology.
BibTeX
@article{wu2024development,
  author = {Chien-Yu Wu and Hsiou‐Yu Ding and Tzi‐Yuan Wang and Chunwei Liu and Jiumn‐Yih Wu and Te‐Sheng Chang},
  title = {{Development of a New Isoxsuprine Hydrochloride-Based Hydroxylated Compound with Potent Antioxidant and Anti-Inflammatory Activities}},
  journal = {Journal of Microbiology and Biotechnology},
  year = {2024},
  doi = {10.4014/jmb.2405.05031},
}
Figure